Correction: Honda et al. Visual Evaluation of Ultrafast MRI in the Assessment of Residual Breast Cancer After Neoadjuvant Systemic Therapy: A Preliminary Study Association with Subtype. Tomography 2022, 8, 1522–1533
Maya Honda, Masako Kataoka, Mami Iima, Rie Ota, Akane Ohashi, Ayami Ohno Kishimoto, Kanae Kawai Miyake, Marcel Dominik Nickel, Yosuke Yamada, Masakazu Toi, Yuji Nakamoto

Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMRI in cancer diagnosis · Breast Cancer Treatment Studies · Advanced MRI Techniques and Applications
This correction addresses several errors identified in the original publication [1].
The definitions for previously undefined abbreviations have been added to the manuscript as follows:
- In the Abstract, Section 2.4 and Results, “ROC” and “AUC” were expanded to “receiver operating characteristic (ROC)” and “area under the ROC curve (AUC)”, respectively.
- In the Abstract, Introduction and Results, “DCE” was expanded to “dynamic contrast-enhanced (DCE)”.
- In the Introduction, “CR” and “HER2” were expanded to “complete response (CR)” and “human epidermal growth factor receptor 2 (HER2)”, respectively.
- In Section 3, “CDK 4/6” was expanded to “cyclin-dependent kinases 4 and 6 (CDK 4/6)”.
- In the Figure 1 legend, “UF-DCE” was expanded to “ultrafast DCE”.
- In the Figure 2 legend, the text “UF-DCE MRI: ultrafast DCE MRI” has been corrected to “UF-DCE MRI: ultrafast dynamic contrast-enhanced MRI”.
- In the Figure 7 legend, “CR” and “ultrafast-DCE” have been corrected to “complete response” and “ultrafast dynamic contrast-enhanced”, respectively.
- In the Figure 8 legend, “CDK 4/6” and “DCE” have been corrected to “cyclin-dependent kinases 4 and 6” and “dynamic contrast-enhanced”, respectively.
The previously published number of lesions achieving pathological complete response (pCR) was incorrect.
A correction has been made to the first paragraph in Results section:
A total of 55 lesions in 55 patients were evaluated, of which 22 lesions achieved pCR.
Table 2 as published contained a mistake. The data columns for pCR and non-pCR was reversed. The corrected Table 2 appears below.
The incorrect Data Availability Statement (“not applicable”) was revised to accurately reflect the availability of our research data. The updated statement is as follows: The data presented in this study are available on request from the corresponding author due to institutional ethical restrictions concerning patient privacy. Only anonymized, analyzed data (excluding patient identifiable information and images) can be considered for sharing, contingent upon review and approval by our institutional review board.
The authors state that the scientific conclusions are unaffected. These corrections were approved by the Academic Editor. The original publication has also been updated.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Honda M. Kataoka M. Iima M. Ota R. Ohashi A. Kishimoto A.O. Miyake K.K. Nickel M.D. Yamada Y. Toi M. Visual Evaluation of Ultrafast MRI in the Assessment of Residual Breast Cancer After Neoadjuvant Systemic Therapy: A Preliminary Study Association with Subtype Tomography 202281522153310.3390/tomography 803012535736873 PMC 9230716 · doi ↗ · pubmed ↗
